James S Blachly

59PUBLICATIONS
270CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Aug 25, 2026
Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

|May 08, 2026
Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Apr 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Clive S Zent, Enrico Tiacci, Robert J Kreitman

|Apr 06, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

Pageof 10

Frequent Collaborators

13 joint publications

Shelley Orwick

11 joint publications

Alice S Mims

10 joint publications

Krzysztof Mrózek

6 joint publications

Rosa Lapalombella